What Reta Actually Does To Your Muscle (First DXA Data)

Retatrutide is the most powerful weight loss drug ever tested in a clinical trial, and the first body composition data just showed exactly what that power costs if you are not paying attention.

To understand what the scan data means, you need the full picture first. Retatrutide works by activating three receptors at once: the GLP-1 receptor, which reduces appetite and slows gastric emptying; the GIP receptor, which amplifies the insulin response and adds to the appetite suppression; and the glucagon receptor, which was supposed to be the thing that made retatrutide special. The theory was that the glucagon component would shift your metabolism toward burning fat specifically, and that this would mean the weight you lost would come disproportionately from fat rather than from muscle. That was the hypothesis going in.

The first thing the DXA data tells you is that the drug works at a scale nothing else has reached. In the phase 2 trial published in the New England Journal of Medicine, participants on the 12 milligram dose lost an average of 24.2 percent of their body weight at 48 weeks. That is not a rounding error above tirzepatide. That is a different category of weight loss entirely.

Now the Lancet body composition substudy scanned 103 people with type 2 diabetes using something called dual-energy X-ray absorptiometry, or DXA, which is the method that measures bone, fat tissue, and lean tissue separately by passing two different energy beams through the body and reading how each tissue absorbs them. It is the gold standard for this kind of measurement precisely because it separates fat mass from lean mass with a level of precision that a standard scale or even a DEXA-adjacent method like BIA cannot match. These 103 participants were scanned at the start of the study and again at 36 weeks.

At the 12 milligram dose, total fat mass dropped by 23.2 percent. Visceral fat, which is the fat stored inside the abdominal cavity around your liver, pancreas, and other organs, dropped by 31.4 percent. That visceral number matters because visceral fat is more metabolically damaging than subcutaneous fat, and a disproportionate reduction there is a meaningful signal for cardiometabolic risk reduction. So far, the drug looks extraordinary.

Here is where the picture gets more complicated.

Of the total weight lost, roughly 75 to 80 percent was fat mass and 20 to 25 percent was lean mass. If you have been following the GLP-1 space at all, you have probably heard this ratio described as acceptable, and in isolation it actually is. Tirzepatide, based on the SURMOUNT-1 body composition substudy, comes in at approximately the same ratio, about 75 percent fat and 25 percent lean. Semaglutide is worse, sitting closer to 60 percent fat and 40 percent lean. So by that comparison, retatrutide looks comparable to or slightly better than tirzepatide, and clearly better than semaglutide.

But ratios hide something that absolute numbers reveal.

When you lose 24 kilograms on the 12 milligram dose of retatrutide, and 20 to 25 percent of that is lean mass, you are looking at roughly 5 to 6 kilograms of lean tissue lost. That is 11 to 13 pounds. The percentage reads fine on paper. The kilogram number tells a different story. Because the drug produces so much total weight loss, even a lean mass ratio that competes favorably with other drugs still produces a larger absolute lean mass loss than anything else on the market. The denominator is just bigger.

This matters because lean mass is not just an aesthetic concern. Muscle tissue is the largest site of glucose disposal in the body, meaning it is where blood sugar goes when insulin signals cells to absorb it. Losing a significant amount of muscle while treating type 2 diabetes creates a partial contradiction at the mechanistic level, because you are improving insulin sensitivity through weight and fat loss on one side while reducing the tissue responsible for glucose uptake on the other.

Now back to the glucagon hypothesis, because the scan data has something direct to say about it. The original reasoning was that glucagon receptor activation would drive hepatic fat oxidation and increase energy expenditure in a way that preferentially targeted fat stores and spared lean tissue. There is real science behind this. Research published in Cell Reports Medicine showed that glucagon receptor activation does upregulate amino acid catabolism in the liver, which is coupled to increased energy expenditure. The mechanism is real. But what the DXA data shows is that having a real mechanism does not mean the clinical outcome matches the prediction. The lean mass ratio in retatrutide looks essentially the same as tirzepatide, which has no glucagon receptor component at all. Whatever the glucagon receptor is doing to energy expenditure, it is not translating into a meaningfully better lean mass preservation outcome at the whole-body level. The ratio is comparable to a drug that does not even use that pathway.

That gap between the theory and the scan data is worth sitting with, because it changes what you should expect from the drug and what you need to do yourself.

The practical implication is direct. If you are losing weight at the rate retatrutide produces and you are not doing resistance training with enough frequency and load to give your body a reason to hold onto muscle tissue, the lean mass loss embedded in that 20 to 25 percent ratio will accumulate into a significant number. The drug reduces appetite and drives fat loss. It does not detect that you need muscle and route the deficit away from it. Muscle is retained when two conditions are met: there is a mechanical stimulus telling the body that the tissue is being used and needs to be preserved, and there is sufficient dietary protein to supply the amino acids for muscle protein synthesis. Without both of those, the body in a significant caloric deficit will pull from lean tissue as part of its energy balance equation, regardless of what receptor the drug is activating.

One gram of protein per pound of goal body weight, combined with resistance training three to five times per week, is not a luxury add-on to a retatrutide protocol. It is the variable that determines whether the weight you lose is mostly fat or a mix that includes a meaningful chunk of muscle you will need later.

The drug is a tool for producing an energy deficit at a scale that was not clinically achievable before. What you do with the conditions that deficit creates is still biology you have to manage yourself. Retatrutide does not change that. The scan data just makes it clearer.

---

References

1. Retatrutide Body Composition Substudy, 2025, The Lancet Diabetes & Endocrinology, Vol 13(8), 674-684. Phase 2, 42 centers, 103 DXA-completed participants with T2D. Fat mass reduction: 23.2% at 12mg. Lean mass: 20-25% of total weight lost. Visceral fat: -31.4% at 12mg.
2. SURMOUNT-1 Body Composition Substudy (Tirzepatide), 2025, Lancet Diabetes Endocrinol. PMC11965027. ~75% fat / 25% lean mass ratio.
3. STEP 1 Body Composition Substudy (Semaglutide), PMC8089287. ~60% fat / 40% lean mass ratio.
4. Jastreboff et al., 2023, NEJM. Retatrutide phase 2 trial (N=338): 24.2% weight loss at 48 weeks (12mg). DOI: 10.1056/NEJMoa2301972.
5. Sherwood et al., 2022, Cell Reports Medicine. GCGR activation upregulates hepatic amino acid catabolism, coupled to energy expenditure increase. PMC9729826.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness